Oncology Ventures has closed its oversubscribed second fund, securing $62 million to advance cancer care innovation. Surpassing its $50 million target, the new fund nearly doubles the size of its predecessor. The firm will continue investing in technologies that make cancer treatment more accessible, affordable, and understandable for patients.
Strategic Focus on a Growing Market
The fund targets the essential tools of the oncology sector, a $225 billion market expanding 12% annually. This area is a primary cost driver for employers and health plans, creating a significant opportunity for innovation. Oncology Ventures aims to back the foundational technologies that support the entire cancer care ecosystem.
Founder Ben Freeberg emphasized the mission's urgency, noting many of the 1,700 daily U.S. cancer deaths are preventable. The firm is dedicated to closing critical gaps in early detection, standardized treatment, and patient navigation. This focus reflects a commitment to improving outcomes by addressing systemic challenges in care.
A Powerful Network of Partners
A key strength is the firm's network of limited partners, which includes institutions treating one-third of all U.S. cancer patients. This collaboration provides portfolio companies with direct access to clinical expertise and real-world settings. The network serves as a powerful catalyst for validating and scaling new healthcare technologies.
Fund II sees the return of prominent partners like Moffitt Cancer Center, City of Hope, and Cardinal Health. They are joined by new investors, including anchor partner Texas Oncology, the nation's largest physician-led oncology practice. Other additions like Fred Hutch Cancer Center further bolster the fund's strategic reach.
Demonstrating Tangible Impact
The firm's portfolio companies have already demonstrated significant, measurable results within the healthcare system. For instance, Risa generated $2 million in annual savings at a single health system through its platform. Meanwhile, IgniteData drastically improved clinical trial efficiency, saving 70 hours per patient for research coordinators.
The impact extends directly to patient care, showcasing the fund's human-centric investment thesis. Tono has supported over 15,000 patients in managing the difficult side effects of cancer treatment. Furthermore, Concr's platform has been shown to improve median survival for certain cancer patients dramatically.
Guidance from Industry Leaders
Oncology Ventures is guided by a distinguished advisory board of leaders from the healthcare and investment sectors. These experts provide invaluable strategic counsel, leveraging their deep industry knowledge to support the fund's mission. Their collective experience helps navigate the complex oncology landscape and identify high-potential ventures.
The board includes prominent figures such as Dr. Karen Knudsen, CEO of The Parker Institute, and Nancy Brown of Oak HC/FT. They are joined by luminaries like Dr. Lee Newcomer, former CMO of UnitedHealth Group, and Emily Melton of Threshold Ventures. This high-caliber advisory team underscores the firm's credibility and strategic advantage.
The closing of its $62 million Fund II positions Oncology Ventures to accelerate progress in the fight against cancer. By combining strategic capital with an unparalleled network of clinical partners, the firm is equipped to support transformative technologies. This new fund reinforces its commitment to fostering innovations that will redefine cancer care and improve patient outcomes.